Assenagon Asset Management S.A. Sells 41,531 Shares of Aptinyx Inc. (NASDAQ:APTX)

Assenagon Asset Management S.A. reduced its stake in Aptinyx Inc. (NASDAQ:APTXGet Rating) by 35.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,283 shares of the company’s stock after selling 41,531 shares during the period. Assenagon Asset Management S.A.’s holdings in Aptinyx were worth $28,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Jane Street Group LLC raised its stake in Aptinyx by 84.9% in the first quarter. Jane Street Group LLC now owns 38,129 shares of the company’s stock worth $87,000 after buying an additional 17,504 shares in the last quarter. Cetera Advisor Networks LLC bought a new position in shares of Aptinyx during the first quarter valued at approximately $92,000. Dimensional Fund Advisors LP increased its stake in shares of Aptinyx by 13.5% during the first quarter. Dimensional Fund Advisors LP now owns 140,711 shares of the company’s stock valued at $320,000 after purchasing an additional 16,774 shares in the last quarter. Northern Trust Corp increased its stake in shares of Aptinyx by 203.7% during the first quarter. Northern Trust Corp now owns 219,698 shares of the company’s stock valued at $498,000 after purchasing an additional 147,357 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Aptinyx by 116.4% during the second quarter. Renaissance Technologies LLC now owns 568,914 shares of the company’s stock valued at $317,000 after purchasing an additional 305,988 shares in the last quarter. 45.93% of the stock is owned by institutional investors.

Aptinyx Price Performance

Shares of NASDAQ APTX opened at $0.44 on Friday. Aptinyx Inc. has a fifty-two week low of $0.20 and a fifty-two week high of $3.76. The company has a 50 day simple moving average of $0.32 and a two-hundred day simple moving average of $0.40. The company has a market capitalization of $29.80 million, a price-to-earnings ratio of -0.41 and a beta of 1.05. The company has a debt-to-equity ratio of 0.51, a quick ratio of 27.45 and a current ratio of 27.45.

Aptinyx (NASDAQ:APTXGet Rating) last announced its earnings results on Tuesday, November 8th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. Analysts expect that Aptinyx Inc. will post -0.97 EPS for the current fiscal year.

Aptinyx Profile

(Get Rating)

Aptinyx Inc is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G.

Read More

Want to see what other hedge funds are holding APTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aptinyx Inc. (NASDAQ:APTXGet Rating).

Institutional Ownership by Quarter for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.